Development of a highly specialized cDNA array for the study and diagnosis of epithelial ovarian cancer.

Ovarian cancer is a major cause of cancer death in women. Unfortunately, the molecular pathways underlying ovarian cancer progression are poorly understood, making the development of novel diagnostic and therapeutic strategies difficult. On the basis of our previous observations obtained from serial analysis of gene expression, we have constructed a specialized cDNA array for the study of ovarian cancer. Small, specialized arrays have several practical advantages and can reveal information that is lost in the "noise" generated by irrelevant genes present in larger arrays. The array, which we named Ovachip, contains 516 cDNAs chosen from our serial analysis of gene expression and cDNA array studies for their relevance to ovarian cancer. The gene expression patterns revealed with the Ovachip are highly reproducible and extremely consistent among the different ovarian specimens tested. This array was extremely sensitive at differentiating ovarian cancer from colon cancer based on expression profiles. The Ovachip revealed clusters of coordinately expressed genes in ovarian cancer. One such cluster, the IGF2 cluster, is particularly striking and includes the insulin-like growth factor II, the cisplatin resistance-associated protein, the checkpoint suppressor 1, the cyclin-dependent kinase 6, and a protein tyrosine phosphatase receptor. We also identified a cluster of down-regulated genes that included the cyclin-dependent kinase 7 and cyclin H. Thus, the Ovachip allowed us to identify previously unidentified clusters of differentially expressed genes that may provide new paradigms for molecular pathways important in ovarian malignancies. Because of the relevance of the arrayed genes, the Ovachip may become a powerful tool for investigators in the field of ovarian cancer and may facilitate progress in understanding the etiology of this disease and in its clinical management.

[1]  R. Fisher,et al.  Chemotherapy of ovarian cancer. , 1978, The Surgical clinics of North America.

[2]  L. Dubeau The cell of origin of ovarian epithelial tumors and the ovarian surface epithelium dogma: does the emperor have no clothes? , 1999, Gynecologic oncology.

[3]  J. Sudbø,et al.  Gene-expression profiles in hereditary breast cancer. , 2001, The New England journal of medicine.

[4]  M. Ko,et al.  Genome-wide expression profiling of mid-gestation placenta and embryo using a 15,000 mouse developmental cDNA microarray. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[5]  C. Garrett,et al.  Protooncogene amplification and tumor ploidy in human ovarian neoplasms. , 1990, Human pathology.

[6]  J. Guastalla,et al.  [Advanced ovarian cancer]. , 1995, Soins; la revue de reference infirmiere.

[7]  D R Schwartz,et al.  Coordinately up-regulated genes in ovarian cancer. , 2001, Cancer research.

[8]  P. Kaldis,et al.  Analysis of CAK activities from human cells. , 2000, European journal of biochemistry.

[9]  R. Spang,et al.  Predicting the clinical status of human breast cancer by using gene expression profiles , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[10]  N. Niikawa,et al.  Frequent loss of imprinting of the H19 and IGF-II genes in ovarian tumors. , 1998, American journal of medical genetics.

[11]  X. Matías-Guiu,et al.  Molecular pathology of ovarian carcinomas , 1998, Virchows Archiv.

[12]  F. Casagrande,et al.  Differential expression of G1 cyclins and cyclin-dependent kinase inhibitors in normal and transformed melanocytes. , 1998, Investigative ophthalmology & visual science.

[13]  G. Riggins,et al.  Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. , 2000, Cancer research.

[14]  P. Pharoah,et al.  Frequent loss of BRCA1 mRNA and protein expression in sporadic ovarian cancers , 2000, International journal of cancer.

[15]  R. L. Baldwin,et al.  BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study. , 2000, Cancer research.

[16]  D. Botstein,et al.  Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[17]  M. Burg Advanced ovarian cancer , 2001, Current treatment options in oncology.

[18]  A. Schäffer,et al.  Chromosome abnormalities in ovarian adenocarcinoma: III. Using breakpoint data to infer and test mathematical models for oncogenesis , 2000, Genes, chromosomes & cancer.

[19]  Roger E Bumgarner,et al.  Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas. , 1999, Gene.

[20]  N. Sampas,et al.  Molecular classification of cutaneous malignant melanoma by gene expression profiling , 2000, Nature.

[21]  D. Lockhart,et al.  Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[22]  J. Bartek,et al.  Expression of CDK7/CAK in normal and tumour cells of diverse histogenesis, cell‐cycle position and differentiation , 1996, International journal of cancer.

[23]  D. Katsaros,et al.  Transforming growth factor-beta isoform expression in human ovarian tumours. , 1997, European journal of cancer.

[24]  G. Getz,et al.  Coupled two-way clustering analysis of gene microarray data. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[25]  H. Ngan,et al.  Loss of imprinting of the IGF-II and H19 genes in epithelial ovarian cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  K. Alitalo,et al.  The related FLT4, FLT1, and KDR receptor tyrosine kinases show distinct expression patterns in human fetal endothelial cells , 1993, The Journal of experimental medicine.

[27]  S. Rafii,et al.  Inhibition of both paracrine and autocrine VEGF/ VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[28]  L. Hartmann,et al.  Human epithelial ovarian cancer allelotype. , 1993, Cancer research.

[29]  J. Berek,et al.  Advanced ovarian cancer. Tumour markers. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  M Aickin,et al.  Chromosome abnormalities in ovarian adenocarcinoma: I. nonrandom chromosome abnormalities from 244 cases , 1999, Genes, chromosomes & cancer.

[31]  N. Auersperg,et al.  E-cadherin induces mesenchymal-to-epithelial transition in human ovarian surface epithelium. , 1999, Proceedings of the National Academy of Sciences of the United States of America.